Veterinary Therapeutics Market - Global Forecast 2025-2032

The veterinary therapeutics market is rapidly evolving, shaped by innovation, regulatory shifts, and changes in animal care demand. This report offers senior decision-makers a comprehensive overview of strategic opportunities and emerging trends transforming animal health solutions worldwide.

Market Snapshot: Veterinary Therapeutics Market Size and Growth

The Veterinary Therapeutics Market grew from USD 40.77 billion in 2024 to USD 43.75 billion in 2025. It is expected to continue growing at a CAGR of 7.44%, reaching USD 72.42 billion by 2032. Global expansion is fueled by a combination of increasing pet ownership, modernization of livestock management, and heightened scrutiny regarding animal health and product quality. These trends are catalyzing investment in advanced biologics and sustainable manufacturing practices, while regional supply chain variations and digitalization foster new value creation models.

Scope & Segmentation

• Product Types: Biologics (cell therapies, monoclonal antibodies, recombinant proteins), Feed Additives (enzymes, prebiotics, probiotics), Parasiticides (ectoparasiticides, endectocides), Pharmaceuticals (anti-inflammatories, antibiotics, hormones), Vaccines (inactivated, live attenuated, recombinant)
• Animal Categories: Aquaculture (crustaceans, freshwater fish, marine fish), Companion Animals (avian, canine, feline, rodents), Equine (performance, racing, recreational horses), Livestock (cattle, poultry, sheep & goats, swine)
• Administration Routes: Inhalation, Oral, Parenteral (intradermal, intramuscular, intravenous, subcutaneous), Topical
• Disease Profiles: Behavioral disorders, Infectious diseases, Metabolic disorders, Musculoskeletal disorders, Parasitic diseases, Reproductive disorders
• End Users: Ambulatory services, Online channels, Retail pharmacies, Veterinary hospitals
• Distribution Channels: Direct sales, E-commerce, Hospital pharmacies, Retail pharmacies
• Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland), Middle East (UAE, Saudi Arabia, Qatar, Turkey, Israel), Africa (South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Key Companies Analyzed: Zoetis Inc., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, Bayer Aktiengesellschaft, Ceva Santé Animale S.A., Virbac S.A., Vetoquinol S.A., Dechra Pharmaceuticals PLC, Phibro Animal Health Corporation

Key Takeaways for Senior Decision-Makers

• Biologics and advanced regenerative therapies are gaining traction across both companion animal and livestock markets, reducing reliance on conventional small-molecule drugs.
• Digital transformation, including the integration of telemedicine and real-time diagnostics, is enhancing accuracy, early intervention, and overall animal health management efficiency.
• Feed additives based on enzymes and probiotics provide a sustainable, preventative approach, aligning with environmental and food safety requirements in developed and emerging economies alike.
• Stakeholders face a complex global regulatory environment, which demands agile compliance infrastructure and increases the importance of collaborative product development and harmonized approval processes.
• Regional expansion strategies are shaped by varied regulatory landscapes, fluctuating consumer expectations, and the need for resilient, diversified supply chains.
• Mergers, acquisitions, and cross-sector innovation partnerships remain key to consolidating competitive positioning and accelerating market entry for new therapeutic modalities.

Tariff Impact: 2025 United States Actions

The imposition of new tariffs by the United States in 2025 has placed upward pressure on the cost of imported ingredients and materials required for veterinary therapeutics. Many producers have responded by exploring near-shoring options, restructuring supply agreements, or localizing manufacturing. While larger organizations are leveraging the situation to expand domestic capabilities, smaller firms face operational pressures stemming from higher costs and transitional compliance requirements. Proactive diversification of sourcing and engagement with regulatory authorities are essential for sustaining supply resilience under prevailing trade conditions.

Methodology & Data Sources

This research draws upon primary interviews with senior executives and veterinary professionals across major companies and regulatory agencies, complemented by secondary analysis of peer-reviewed literature, industry reports, and public filings. Data is validated through triangulation, robust modeling, and multiple verification steps, ensuring integrity and actionable accuracy for all findings reported.

Why This Report Matters

• Enables senior leadership to benchmark strategic investments by understanding innovation pipelines, technology adoption, and emerging regulatory demands within the veterinary therapeutics sector.
• Offers region-specific insights, highlighting growth opportunities and risks associated with market access, compliance, and supply chain adaptation.
• Equips organizations to anticipate competitive moves and customer priorities, driving informed decision-making and sustainable differentiation.

Conclusion

The veterinary therapeutics market is in the midst of significant change, marked by scientific progress, regulatory evolution, and new digital models. Organizations that pursue innovation, expand supply chain resilience, and tailor strategies to regional dynamics will be positioned to lead and capitalize on future opportunities.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.